Revascularization Strategies in STEMI with Multivessel Disease: Deciding on Culprit Versus Complete—Ad Hoc or Staged

[11] Rutherford BD(2016)PCI strategies in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease J Am Coll Cardiol 68 1066-1081

[12] McConahay DR(2004)Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for acute myocardial infarction (HELP AMI) study Int J Cardiovasc Interv 6 128-133

[13] Muller DW(2010)A randomized trial of target-vessel versus multi-vessel revascularization in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up Heart 96 662-667

[14] Topol EJ(2015)Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial J Am Coll Cardiol 65 963-972

[15] Ellis SG(1999)TIMI Study Group. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction J Am Coll Cardiol 34 974-982

[16] Park DW(2010)Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction J Am Coll Cardiol Intv 3 1274-1281

[17] Clare RM(2010)Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines EuroIntervention 5 968-975

[18] Schulte PJ(2012)Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomized clinical trial Neth Heart J 20 347-353

[19] O’Gara PT(2015)Lancet. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial Lancet 386 665-671

[20] Kushner FG(2016)Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents Am Heart J 179 157-165

[11] Rutherford BD(2016)PCI strategies in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease J Am Coll Cardiol 68 1066-1081

[12] McConahay DR(2004)Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for acute myocardial infarction (HELP AMI) study Int J Cardiovasc Interv 6 128-133

[13] Muller DW(2010)A randomized trial of target-vessel versus multi-vessel revascularization in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up Heart 96 662-667

[14] Topol EJ(2015)Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial J Am Coll Cardiol 65 963-972

[15] Ellis SG(1999)TIMI Study Group. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction J Am Coll Cardiol 34 974-982

[16] Park DW(2010)Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction J Am Coll Cardiol Intv 3 1274-1281

[17] Clare RM(2010)Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines EuroIntervention 5 968-975

[18] Schulte PJ(2012)Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomized clinical trial Neth Heart J 20 347-353

[19] O’Gara PT(2015)Lancet. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial Lancet 386 665-671

[20] Kushner FG(2016)Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents Am Heart J 179 157-165